CY1107561T1 - Εμβoλιο kata του πνευμονιοκοκκου - Google Patents

Εμβoλιο kata του πνευμονιοκοκκου

Info

Publication number
CY1107561T1
CY1107561T1 CY20071100247T CY071100247T CY1107561T1 CY 1107561 T1 CY1107561 T1 CY 1107561T1 CY 20071100247 T CY20071100247 T CY 20071100247T CY 071100247 T CY071100247 T CY 071100247T CY 1107561 T1 CY1107561 T1 CY 1107561T1
Authority
CY
Cyprus
Prior art keywords
kata
vaccine
pulmonary
antigen
relates
Prior art date
Application number
CY20071100247T
Other languages
Greek (el)
English (en)
Inventor
Carine Capiau
Marguerite Deschamps
Pierre Michel Desmons
Craig A J Laferriere
Jan Poolman
Jean-Paul Prieels
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1107561T1 publication Critical patent/CY1107561T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20071100247T 1999-03-19 2007-02-21 Εμβoλιο kata του πνευμονιοκοκκου CY1107561T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
EP00916983A EP1162999B1 (en) 1999-03-19 2000-03-17 Vaccine against Streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
CY1107561T1 true CY1107561T1 (el) 2013-03-13

Family

ID=27451884

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071100247T CY1107561T1 (el) 1999-03-19 2007-02-21 Εμβoλιο kata του πνευμονιοκοκκου
CY20081100394T CY1107390T1 (el) 1999-03-19 2008-04-10 Εμβολιο εναντι αντιγονων απο βακτηριδια
CY2009014C CY2009014I1 (el) 1999-03-19 2009-09-24 Εμβολιο εναντι αντιγονων απο βακτηριδια

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20081100394T CY1107390T1 (el) 1999-03-19 2008-04-10 Εμβολιο εναντι αντιγονων απο βακτηριδια
CY2009014C CY2009014I1 (el) 1999-03-19 2009-09-24 Εμβολιο εναντι αντιγονων απο βακτηριδια

Country Status (32)

Country Link
US (8) US20030147922A1 (instruction)
EP (6) EP1162998B1 (instruction)
JP (4) JP4846906B2 (instruction)
KR (3) KR100798212B1 (instruction)
CN (3) CN1192798C (instruction)
AR (3) AR022963A1 (instruction)
AT (3) ATE346608T1 (instruction)
AU (3) AU750788B2 (instruction)
BE (1) BE1025464I2 (instruction)
BR (4) BR0009154A (instruction)
CA (3) CA2366314C (instruction)
CY (3) CY1107561T1 (instruction)
CZ (3) CZ303653B6 (instruction)
DE (4) DE122009000054I1 (instruction)
DK (2) DK1163000T3 (instruction)
ES (3) ES2275499T3 (instruction)
FR (1) FR10C0008I2 (instruction)
HK (3) HK1043730A1 (instruction)
HU (4) HU229968B1 (instruction)
IL (5) IL145043A0 (instruction)
LU (1) LU91652I2 (instruction)
MX (1) MXPA01009452A (instruction)
MY (2) MY125202A (instruction)
NL (1) NL300415I1 (instruction)
NO (4) NO20014322L (instruction)
NZ (3) NZ513841A (instruction)
PL (3) PL204890B1 (instruction)
PT (2) PT1163000E (instruction)
SI (2) SI1162999T1 (instruction)
TR (3) TR200102739T2 (instruction)
TW (3) TWI286938B (instruction)
WO (3) WO2000056360A2 (instruction)

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69737413T2 (de) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
PT1163000E (pt) * 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigénios de bactérias
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP4646516B2 (ja) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
EP1551869A2 (en) * 2002-10-15 2005-07-13 Intercell AG Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
DK2395073T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying.
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CN1787839B (zh) 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
DK1601689T3 (da) * 2003-03-13 2008-03-25 Glaxosmithkline Biolog Sa Oprensningsfremgangsmåde for bakterielt cytolysin
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK1858919T3 (da) 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
EP2351772B1 (en) 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) * 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
RU2442825C2 (ru) 2005-04-18 2012-02-20 Новартис Вэксинес Энд Дайэгностикс Инк. Иммуногенные композиции, способы получения таких композиций и плазмида, включенная в такие композиции
AU2006263936B2 (en) 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
UA96583C2 (uk) * 2005-12-22 2011-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Вакцина, що містить кон'югати капсулярного полісахариду streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX2008009280A (es) * 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
KR101838938B1 (ko) * 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
PE20080129A1 (es) * 2006-03-30 2008-04-08 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008020335A2 (en) * 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CL2007002909A1 (es) * 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2008267208B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
IN2012DN00446A (instruction) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN104587462B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinação de vacinas contra doenças do trato respiratório.
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506165TA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP2515934B1 (en) 2009-12-22 2017-05-17 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
HUE048398T2 (hu) * 2010-06-04 2020-07-28 Wyeth Llc Vakcinakészítmények
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 페트르 젠나디에비치 아파린 시겔라 소네이 박테리아의 세포외 다당류, 이를 제조하는 방법, 이를 함유한 백신 및 약제 조성물
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
KR101728483B1 (ko) 2012-05-04 2017-04-19 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
MX2015002482A (es) 2012-10-03 2016-01-08 Glaxosmithkline Biolog Sa Composicion inmunogenica.
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR112015008417A8 (pt) * 2012-10-17 2019-09-10 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, uso de uma composição imunogênica
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1223273A1 (zh) 2014-01-21 2017-07-28 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
RU2018104362A (ru) 2015-07-07 2019-08-08 Аффирис Аг ВАКЦИНЫ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
PE20240927A1 (es) 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
WO2017033123A1 (en) 2015-08-25 2017-03-02 Babita Agrawal Immunomodulatory compositions and methods of use thereof
CN108290960B (zh) 2015-10-08 2023-06-09 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
JP7099956B2 (ja) 2015-12-04 2022-07-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
JP7001687B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
JP7001686B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
CN110520154B (zh) * 2017-03-15 2023-08-04 株式会社Lg化学 多价肺炎链球菌疫苗组合物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
EP3720483A2 (en) 2017-12-06 2020-10-14 Merck Sharp&Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7288451B2 (ja) 2018-02-05 2023-06-07 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質複合体組成物
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN112118863B (zh) 2018-04-11 2025-05-30 恩特罗姆公司 用于预防和治疗癌症的抗原肽
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
BR112021000529A2 (pt) 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarídeos secos
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
KR102735230B1 (ko) 2018-12-19 2024-11-29 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
JP7644454B2 (ja) * 2019-01-11 2025-03-12 ノースウェスタン ユニバーシティ 原核細胞溶解物におけるバイオコンジュゲートワクチンの合成
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112022009100A2 (pt) 2019-11-15 2022-07-26 Enterome S A Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
JP7664386B2 (ja) 2020-10-27 2025-04-17 ファイザー・インク 大腸菌組成物およびその方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
EP4463186A1 (en) 2022-01-13 2024-11-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
CN120404993A (zh) * 2025-07-03 2025-08-01 成都迈科康生物科技有限公司 一种检测样本中mpl的方法及其相关应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) * 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 존 더블유.로우 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CZ394297A3 (cs) 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
AU732520B2 (en) 1996-05-01 2001-04-26 Rockefeller University, The Choline binding proteins for anti-pneumococcal vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU739129B2 (en) 1997-06-03 2001-10-04 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
WO1999051266A2 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
ATE422899T1 (de) * 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
PT1163000E (pt) 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigénios de bactérias
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
NL300415I2 (instruction) 2016-12-13
ES2300255T3 (es) 2008-06-16
NO20014325L (no) 2001-11-14
IL145044A0 (en) 2002-06-30
CZ301445B6 (cs) 2010-03-03
CZ20013379A3 (cs) 2002-03-13
NO330736B1 (no) 2011-06-27
AR022965A1 (es) 2002-09-04
MY125202A (en) 2006-07-31
WO2000056359A3 (en) 2001-02-01
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
HK1043728A1 (en) 2002-09-27
US20030147922A1 (en) 2003-08-07
DE60032120D1 (de) 2007-01-11
SI1163000T1 (sl) 2008-06-30
AR022964A1 (es) 2002-09-04
US8926985B2 (en) 2015-01-06
JP5551579B2 (ja) 2014-07-16
KR100798212B1 (ko) 2008-01-24
DE60038166T2 (de) 2009-03-12
LU91652I9 (instruction) 2019-01-03
BRPI0009163B1 (pt) 2019-04-09
IL145045A0 (en) 2002-06-30
JP4846906B2 (ja) 2011-12-28
PL355180A1 (en) 2004-04-05
KR20020000549A (ko) 2002-01-05
EP1776962A1 (en) 2007-04-25
NO20014322L (no) 2001-11-14
FR10C0008I1 (fr) 2010-03-26
PL204890B1 (pl) 2010-02-26
AU750913B2 (en) 2002-08-01
WO2000056358A3 (en) 2001-01-04
PL203917B1 (pl) 2009-11-30
LU91652I2 (fr) 2010-10-13
CN1351501A (zh) 2002-05-29
CY2009014I2 (el) 2010-07-28
EP1163000B1 (en) 2008-02-27
NL300415I1 (nl) 2009-12-01
CZ20013378A3 (cs) 2002-03-13
DK1163000T3 (da) 2008-04-28
TWI281403B (en) 2007-05-21
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
NO330532B1 (no) 2011-05-09
IL145043A0 (en) 2002-06-30
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
AU750788B2 (en) 2002-07-25
US9168313B2 (en) 2015-10-27
BR0009163A (pt) 2001-12-26
AU3430700A (en) 2000-10-09
AR022963A1 (es) 2002-09-04
AU3813600A (en) 2000-10-09
BRPI0009163B8 (pt) 2021-05-25
EP1880735A2 (en) 2008-01-23
HUS1500040I1 (hu) 2018-05-28
DE60038166D1 (de) 2008-04-10
PL355264A1 (en) 2004-04-05
KR20020000785A (ko) 2002-01-05
ATE387214T1 (de) 2008-03-15
CN1192798C (zh) 2005-03-16
CA2366314C (en) 2012-01-10
BE1025464I2 (instruction) 2019-03-06
NZ513840A (en) 2004-02-27
NO20014322D0 (no) 2001-09-05
DE60043930D1 (de) 2010-04-15
TWI286938B (en) 2007-09-21
WO2000056358A2 (en) 2000-09-28
US20100119544A1 (en) 2010-05-13
HK1043731A1 (en) 2002-09-27
CN1191852C (zh) 2005-03-09
HUP0200373A2 (en) 2002-06-29
EP1162999A2 (en) 2001-12-19
EP1162998A2 (en) 2001-12-19
FR10C0008I2 (fr) 2012-10-26
ATE459373T1 (de) 2010-03-15
KR20020001785A (ko) 2002-01-09
HU229968B1 (hu) 2015-03-30
WO2000056360A3 (en) 2001-01-25
AU750762B2 (en) 2002-07-25
CA2365296A1 (en) 2000-09-28
EP1880735A3 (en) 2008-03-12
PL355178A1 (en) 2004-04-05
DK1162999T3 (da) 2007-03-26
HUP0200664A2 (en) 2002-06-29
NZ513842A (en) 2004-05-28
EP2277535A2 (en) 2011-01-26
IL145044A (en) 2007-03-08
SI1162999T1 (sl) 2007-04-30
IL145043A (en) 2007-06-17
CN1391481A (zh) 2003-01-15
HK1043730A1 (zh) 2002-09-27
DE122009000054I1 (de) 2009-12-31
HK1043728B (en) 2007-06-22
US20060002961A1 (en) 2006-01-05
MXPA01009452A (es) 2002-08-06
CY2009014I1 (el) 2010-07-28
TR200102735T2 (tr) 2002-04-22
DE60032120T2 (de) 2007-09-20
EP1163000A2 (en) 2001-12-19
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
AU3291900A (en) 2000-10-09
ATE346608T1 (de) 2006-12-15
TR200102739T2 (tr) 2001-12-21
US20110217329A1 (en) 2011-09-08
JP2002540074A (ja) 2002-11-26
ES2339737T3 (es) 2010-05-25
TWI235064B (en) 2005-07-01
US20050031646A1 (en) 2005-02-10
MY125387A (en) 2006-07-31
HK1043731B (en) 2009-01-23
NZ513841A (en) 2001-09-28
PT1162999E (pt) 2007-02-28
TR200102736T2 (tr) 2002-04-22
CY1107390T1 (el) 2010-07-28
HUP0200367A2 (en) 2002-05-29
JP2002539273A (ja) 2002-11-19
HU228499B1 (en) 2013-03-28
EP2277535A3 (en) 2011-03-09
JP2002540075A (ja) 2002-11-26
NO20014323D0 (no) 2001-09-05
BR0009154A (pt) 2001-12-26
JP2011057713A (ja) 2011-03-24
WO2000056359A2 (en) 2000-09-28
BR0009166A (pt) 2001-12-26
CZ303653B6 (cs) 2013-01-30
KR100642044B1 (ko) 2006-11-10
CN1351503A (zh) 2002-05-29
CA2366314A1 (en) 2000-09-28
WO2000056360A2 (en) 2000-09-28
EP1162998B1 (en) 2010-03-03
NO2011014I2 (no) 2011-08-30
US20060093626A1 (en) 2006-05-04
NO20014325D0 (no) 2001-09-05
EP1162999B1 (en) 2006-11-29
NO2011014I1 (no) 2011-09-19

Similar Documents

Publication Publication Date Title
CY1107561T1 (el) Εμβoλιο kata του πνευμονιοκοκκου
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
CY1113530T1 (el) Εμβολιο εναντι του αναπαραγωγικου και αναπνευστικου συνδρομου των χοιρων, βασισμενο στο απομονωθεν στελεχος ja-142
ATE542829T1 (de) Impfstoff
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
DE69519634D1 (de) Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
CY1113826T1 (el) Ανοσοενισχυτικα για εμβολια
CY1112280T1 (el) Συνθεση πολυδυναμου εμβολιου
ATE426412T1 (de) Adjuvante influenza-vakzine
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
EA200801367A1 (ru) Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
HUP9900919A2 (hu) 2,5-D-Mannóz-csoportot tartalmazó B antigén csoportba tartozó II és III típusú streptococcus poliszacharid-fragmentumok és ezeket tartalmazó vakcinakonjugátumok
ATE513560T1 (de) Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
DE69713408D1 (de) Streptococcus equi Impstoff
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
DE60136360D1 (de) Antigen aus streptococcus pyogenes
DK0894500T3 (da) Streptococcus equi-vaccine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DK1227840T3 (da) Adjuverede, genetiske vacciner
CY1116907T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων
TH70240A (th) วัคซีนมีชีวิตที่อ่อนกำลังต่อโรคการอักเสบของเยื่อหุ้มปอดและปอดในสุกร